- Critical Care Symposium to Highlight Newly Validated Risk Assessment Biomarkers
SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- Leading critical care experts will discuss new techniques for assessing risk of acute kidney injury (AKI) at an educational symposium to be held at the Eighteenth International Conference on Continuous Renal Replacement Therapies (CRRT) in San Diego. The symposium, "New AKI Biomarkers: A Revolution in Risk Assessment," will be held on Thursday, February 14, 2013, from 12:40 p.m. to 2:00 p.m. local time. Interested participants can visit http://www.crrtonline.com to register online and can follow via Twitter @ACuteKidneyMan.
Globally, AKI has emerged as a significant and costly threat in the eyes of hospital physicians, particularly those who treat critically ill patients. The condition strikes up to seven percent of the annual estimated 36 million U.S. hospital patients, with intensive care patients at highest risk. If undetected and unchecked, AKI can result in substantial kidney damage that can lower the quality of life, contribute to complications that may heighten risk of readmission, or even result in death.
Symposium attendees will hear newly published research regarding two biomarkers that have been recently shown to be highly accurate in the assessment of AKI risk. Presenting faculty for the event, Dr. John Kellum of the University of Pittsburgh Medical Center, Dr. Andrew Shaw of Duke University Medical Center and Dr. Kianoush Kashani of Mayo Clinic, will also discuss strategies, challenges and advances in the management of AKI patients.
CRRT is one of the leading and most influential conferences of its kind. Topics for this year's conference will include organ dysfunction, controversies in management, and challenges and controversies in renal support as they pertain to critically ill patients. Workshops will also be available, along with special sessions for nurses and allied personnel. Additional information can be found at http://www.crrtonline.com/conference/.
About Astute Medical, Inc.
Named by the Wall Street Journal as one of the Top 10 Healthcare Start-Ups of 2012, Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is community- and hospital-acquired acute conditions that require rapid diagnosis and risk assessment. Astute Medical's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis. For additional information, please visit www.astutemedical.com.
Astute Medical®, the Astute Medical logo, Astute140® and NephroCheck® are registered trademarks of Astute Medical, Inc. in the United States. The NephroCheck logo is a trademark of Astute Medical, Inc. For information regarding trademarks and other intellectual property applicable to this product, including international trademarks, please see AstuteMedical.com/about/intellectual-property.
SOURCE Astute Medical, Inc.